A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from Sequoia at a $1 billion valuation, before its value jumped to $6 billion in October. In less than a year, OpenEvidence has raised $700 million from investors including Google’s venture arm, Nvidia, Kleiner Perkins, David Sacks’ Craft Ventures and Mayo Clinic. The company was founded in 2022 by Daniel Nadler, who previously built Kensho Technologies, an artificial intelligence company that was acquired by Standard & Poor’s for about $700 million in 2018, and by Zachary Ziegler, a Harvard PhD student in AI. Nadler’s newest venture provides a chatbot for doctors, with its AI models having been trained on data and information from top scientific journals, Nadler said in an interview.

Full report : OpenEvidence, which is building “ChatGPT for doctors”, raised $250 million led by Thrive and DST at a $12 billion valuation, up from $6 billion in October and $1 billion in February 2025.